VitaSpring Biomedical Reports Continued Revenue Absence and Net Loss for Six Months Ending July 31, 2024

VitaSpring Biomedical Co., Ltd. has reported its financial results for the six months ending July 31, 2024, revealing a continued absence of revenue, consistent with the previous fiscal period. The company recorded a net loss of $435,493 for the six months, a decrease from the net loss of $658,184 reported for the same period in 2023. Operating expenses also decreased to $435,493 from $658,184 year-over-year, primarily due to reduced selling, general, and administrative expenses, which fell from $353,583 to $218,662 in the most recent quarter.

The company's balance sheet reflects significant changes, with total assets decreasing to $64,334 as of July 31, 2024, down from $137,342 at the end of January 2024. Current assets increased to $45,250, primarily due to prepaid expenses, while long-term assets decreased significantly from $113,715 to $19,084, largely due to the removal of the operating lease right-of-use asset. Current liabilities rose to $3,767,583, compared to $3,487,531 in January, indicating a working capital deficit of $3,722,333.

VitaSpring's operational metrics indicate a stable employee count, with 207,030,030 shares outstanding throughout the reporting period. The company continues to rely on advances from related parties for financing, receiving $11,956 in cash advances during the first half of 2024, compared to $5,277 in the same period last year. The total advances outstanding from related parties increased to $773,436 as of July 31, 2024, up from $425,482 in January 2024.

Management has expressed concerns regarding the company's ability to continue as a going concern, citing minimal cash reserves and recurring operating losses. The company plans to seek additional capital through equity financing and strategic partnerships to fund its operations. However, there is no assurance that such financing will be available on acceptable terms. The financial statements do not include adjustments that might result from this uncertainty, highlighting the precarious position of the company as it navigates its financial challenges.

Looking ahead, VitaSpring aims to enhance its position in the cell medical industry, focusing on research and development of stem cell applications in regenerative medicine. The company is committed to establishing advanced medical research centers and high-standard cell production facilities. Despite the current financial difficulties, management remains focused on strategic initiatives to drive future growth and operational stability.